Biomarin pharmaceutical inc (BMRN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)

114,006

-23,848

-42,522

-110,178

-89,535

-77,211

-124,953

-124,860

-144,901

-117,042

-156,370

-181,268

-563,449

-630,210

-470,873

-524,374

-187,349

-171,799

-310,213

-211,842

-163,355

-133,969

-126,162

-186,627

-174,658

-176,353

-167,375

-119,712

-130,185

-114,347

-88,070

-100,366

-73,437

-53,836

-39,290

195,697

200,297

205,819

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

108,837

105,300

104,226

99,832

94,465

95,671

99,619

93,974

92,082

87,861

79,304

88,026

97,598

96,912

89,691

72,307

55,096

47,187

40,267

42,454

44,684

45,871

38,391

37,478

36,670

36,014

48,425

46,780

45,085

44,335

42,018

39,701

37,059

35,046

34,397

32,866

30,912

27,737

0

0

0

Non-cash interest expense

14,169

13,960

14,482

22,756

26,994

31,186

34,607

33,999

33,146

32,300

31,446

30,769

30,348

29,930

29,526

29,175

28,830

28,493

28,163

27,840

27,527

27,225

25,828

19,051

12,357

5,875

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

(Accretion of discount) Amortization of premium on investments

1,049

2,000

2,308

1,111

1,294

-358

-1,684

-1,709

-3,178

-3,077

-2,781

-2,091

-1,651

-1,300

-1,242

-1,772

-2,069

-2,177

-3,079

-4,411

-5,728

-7,211

-7,498

-6,811

-6,343

-5,899

-5,543

-5,560

-5,073

-4,469

-4,056

-3,721

-3,808

-4,036

-4,002

-4,005

-4,335

-4,453

0

0

0

Stock-based compensation

164,098

159,865

158,321

156,195

154,972

148,819

145,846

144,702

146,197

140,263

144,099

141,341

135,138

134,641

127,786

123,399

119,010

111,525

112,118

103,823

91,835

86,410

76,989

73,316

70,135

64,376

54,564

49,764

47,693

47,340

46,602

46,396

44,913

43,909

42,556

41,066

39,907

38,362

0

0

0

Gain on sale of nonfinancial assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of equity investment

-

-

-

-

-

-

-

-

-

3,252

5,164

5,171

3,144

-108

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on termination of leases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,092

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,707

6,707

6,707

6,704

0

0

0

0

-

-

-

-

Equity in the loss of BioMarin/Genzyme LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-964

-1,153

-888

-1,221

-1,577

-1,849

-2,618

-2,426

0

0

0

-

-

0

0

Net gain from sale of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

902

0

0

0

Deferred income taxes

-71,453

-82,760

-95,423

-48,780

-55,094

-68,378

47,879

37,553

40,917

44,464

-45,504

-59,693

-217,127

-228,054

-310,156

-253,007

-90,395

-76,827

1,385

-35,846

-33,238

-25,617

-2,066

-3,905

-9,041

-8,905

-18,523

-19,786

-10,676

-9,921

-13,091

-2,487

1,165

4,363

-668

-223,584

-226,667

-230,577

0

0

0

Excess tax benefit from stock option exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

603

611

883

733

712

842

583

473

402

471

18

415

618

556

956

541

0

0

0

Unrealized foreign exchange (gain) loss

-10,844

-1,025

4,985

11,274

23,801

17,766

10,087

-5,435

-13,604

-6,258

-828

11,469

9,685

14,481

14,045

17,254

20,415

19,575

19,677

13,641

7,841

832

-3,388

-3,345

-1,029

658

3,375

5,586

5,015

6,529

3,371

-2,717

-5,697

-7,174

-5,148

628

4,561

4,220

0

0

0

Non-cash changes in the fair value of contingent consideration

-7,059

5,205

2,106

12,359

15,925

9,296

19,796

4,975

14,620

10,342

3,175

9,100

-58,744

-57,161

-100,512

-102,129

-25,803

-28,457

15,466

16,802

3,698

11,567

11,583

18,584

13,597

10,197

21,929

13,714

8,358

8,788

-7,510

-10,361

2,893

-1,795

2,997

2,088

-2,842

-3,989

0

0

0

Debt conversion expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,965

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Other

2,043

1,679

1,906

7,722

3,028

2,347

-819

-3,901

-5,628

-5,935

-3,949

-3,437

-779

-336

-2,448

-2,447

-3,119

-2,463

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

18,060

37,852

20,193

7,888

79,707

54,274

99,542

85,838

37,462

25,256

21,058

18,067

49,490

51,483

68,536

29,030

5,622

16,367

22,323

59,154

60,146

25,951

-3,457

7,127

-9,945

8,740

7,455

14,313

14,517

4,227

10,426

-5,663

-177

18,456

28,323

28,924

23,592

13,036

0

0

0

Inventory

129,995

107,554

66,086

72,359

32,855

23,747

26,237

21,028

63,387

96,890

85,595

83,281

76,887

64,512

63,322

63,666

41,930

50,989

28,694

20,852

27,813

22,339

42,227

37,911

27,845

21,102

27,859

22,171

11,758

-1,423

5,197

7,826

13,997

20,420

23,887

28,521

30,306

31,036

0

0

0

Other current assets

28,818

27,008

35,302

20,719

10,579

17,767

-4,376

19,014

20,526

20,687

-85

-12,420

-19,680

-19,316

-52,214

-26,775

-31,721

-25,800

20,398

3,140

4,806

2,211

20,080

2,574

4,596

12,073

-2,872

-4,311

797

3,506

-536

8,375

6,519

-2,543

3,554

1,306

1,737

-3,239

0

0

0

Other assets

11,556

8,895

4,899

-920

-2,384

935

4,557

7,778

3,011

2,439

1,007

4,649

4,274

4,979

6,768

5,093

4,719

3,157

1,199

1,380

5,266

6,516

2,449

302

-4,048

-3,952

-2,522

-1,774

-948

4,076

7,852

8,821

8,476

837

3,068

931

2,856

5,326

0

0

0

Accounts payable and accrued liabilities

24,426

77,089

72,226

33,807

48,206

38,389

35,159

48,814

71,452

45,517

22,915

-1,931

-40,283

-53,205

11,522

36,371

56,790

90,298

8,034

10,481

-176

38,040

39,872

21,925

8,016

20,304

32,948

28,284

26,853

37,411

24,137

13,890

15,801

9,771

-693

-2,274

6,373

2,166

0

0

0

Other long-term liabilities

6,798

3,128

7,556

16,530

10,796

8,914

6,039

4,996

2,640

5,792

2,535

6,104

1,945

-5,413

-4,494

-14,381

-13,053

747

3,999

11,346

11,692

3,093

4,075

6,359

7,372

9,559

2,777

3,816

7,423

6,034

9,568

5,628

2,787

1,962

1,879

2,122

1,411

1,900

0

0

0

Net cash used in operating activities

87,936

48,262

40,293

17,368

7,849

20,208

-14,552

-23,460

29,177

-8,757

-23,581

-72,241

-136,826

-227,837

-293,474

-285,956

-253,142

-219,499

-177,559

-183,266

-181,740

-70,422

-55,512

-56,447

-51,799

-57,335

-36,352

-12,646

-7,249

17,609

5,110

-243

14,743

18,415

3,146

3,342

11,997

18,746

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment

156,824

145,026

136,320

153,325

143,212

144,620

142,431

135,054

160,293

199,219

210,903

194,517

172,266

148,380

200,615

219,075

229,025

227,653

151,611

132,225

137,287

117,062

119,048

107,080

76,974

65,193

49,335

51,146

50,218

44,571

39,356

80,731

73,157

73,219

75,280

28,264

41,594

49,461

0

0

0

Maturities and sales of investments

615,018

740,211

772,349

1,105,242

1,109,166

993,734

957,345

503,312

380,506

425,960

390,446

318,406

336,218

367,569

465,728

554,293

481,843

424,713

862,623

842,847

863,059

808,313

263,494

253,210

275,503

288,643

305,003

285,889

246,331

237,837

220,356

243,399

272,015

281,991

297,716

301,318

268,319

206,361

0

0

0

Purchases of available-for-sale securities

432,284

632,023

724,052

675,615

728,663

634,753

484,851

869,919

746,992

655,447

939,150

771,821

695,223

699,749

400,704

202,835

643,667

873,184

900,971

1,103,379

711,161

507,036

664,788

409,781

410,578

395,042

284,543

287,878

414,376

382,168

276,948

295,335

177,781

215,429

288,071

264,752

232,913

221,659

0

0

0

Proceeds from sale of nonfinancial assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of promissory note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of intangible assets

20,137

18,380

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Business acquisitions, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

538,392

0

0

0

-

-

-

-

9,875

0

0

0

-

0

0

0

-

-

-

-

32,950

0

0

0

Investments in BioMarin/Genzyme LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,743

1,258

1,913

2,568

1,903

2,621

3,416

2,761

3,633

0

0

0

Other

1,075

808

1,747

-23

-21

10

203

1,034

461

1,753

2,108

2,108

1,939

698

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

96,857

-31,026

-53,093

300,555

285,606

264,351

474,860

-357,695

-402,240

-305,459

-754,654

-651,362

-535,999

-484,047

-94,847

169,010

-351,728

-1,179,598

-796,465

-920,863

-516,022

196,327

-572,842

-382,051

-329,434

-298,852

-44,720

-68,980

-233,623

-195,645

-178,206

-215,580

-62,491

-89,560

-68,256

-13,940

-27,775

-101,342

0

0

0

Proceeds from exercises of awards under equity incentive plans

35,929

31,611

33,613

41,575

60,152

67,488

70,383

65,126

60,907

60,859

70,848

91,872

83,792

74,227

61,028

40,632

38,540

63,045

93,784

97,229

88,218

79,904

49,985

54,899

67,711

72,579

105,623

101,557

93,962

83,061

47,823

49,300

44,138

33,592

36,651

31,515

27,053

33,103

0

0

0

Taxes paid related to net share settlement of equity awards

41,419

42,680

42,690

44,205

43,125

35,919

35,824

35,497

38,471

33,507

36,091

33,269

36,616

59,469

56,262

56,247

63,042

22,989

22,490

20,640

8,030

7,768

7,502

7,104

6,645

6,397

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from public offering of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

888,257

888,257

888,257

888,257

117,464

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,965

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

-

-

-

-

1,894

1,894

1,894

1,894

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess tax benefit from stock option exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

603

611

883

733

712

842

583

473

402

471

18

415

618

556

956

541

0

0

0

Principal repayments of financing leases

-5,356

-5,087

-2,025

-1,347

-674

0

0

0

0

-

-

-

-

-588

-528

-527

-1,303

-2,590

-2,082

-2,067

-1,978

-711

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment on maturity of 2013 convertible note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

Repayment of capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

890

801

814

879

601

581

467

195

0

0

0

Net cash used in financing activities

-69,364

-74,674

-445,078

-437,952

-403,223

-388,007

-8,549

468,236

504,123

507,145

513,962

769,031

757,629

727,108

716,713

-16,527

-26,332

925,723

957,727

962,833

962,025

184,198

847,604

851,032

869,813

746,671

81,307

79,314

312,666

312,291

283,172

280,624

39,552

29,338

8,825

7,775

-2,403

3,504

0

0

0

Effect of exchange rate changes on cash

-3,166

902

-1,086

195

157

-598

-974

-14,534

-5,314

-3,231

-11,677

3,467

-7,023

-3,934

2,611

-1,222

1,085

-5,072

-5,362

-2,757

-3,471

-3,398

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

112,263

-56,536

-458,964

-119,834

-109,611

-104,046

450,785

72,547

125,746

189,698

-275,950

48,895

77,781

11,290

331,003

-134,695

-630,117

-478,446

-21,659

-144,053

260,792

306,705

216,440

409,272

485,398

388,254

235

-2,312

71,794

134,255

110,076

64,801

-8,196

-41,807

-56,285

-2,823

-18,181

-79,092

0

0

0

SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for income taxes

11,087

9,726

6,973

5,751

5,851

16,676

17,942

22,412

29,250

23,895

22,438

18,229

29,018

95,857

95,870

96,239

87,941

16,084

27,985

35,709

35,963

34,986

24,110

16,600

14,632

14,897

14,156

13,056

5,489

6,582

6,600

7,011

5,518

4,395

4,063

4,696

3,943

3,581

0

0

0

Cash paid for interest

8,472

8,552

9,879

10,087

11,578

11,623

11,778

9,856

10,072

8,544

0

0

0

-

-

-

-

-

-

-

-

9,324

3,680

3,981

162

2,159

6,306

6,331

8,370

6,665

6,793

6,899

6,871

7,215

7,421

9,236

8,892

10,077

0

0

0

Stock-based compensation capitalized into inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,829

11,399

11,129

11,140

10,774

9,749

8,593

8,166

7,565

7,640

7,181

6,121

5,524

4,876

4,446

4,347

4,362

4,680

5,019

5,298

5,412

5,294

5,232

5,139

0

0

0

Depreciation capitalized into inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,024

16,304

15,182

14,627

13,968

12,920

11,608

10,952

10,784

10,973

11,333

11,016

10,812

10,451

8,880

7,335

0

0

0

-

-

-

-

5,088

0

0

0

SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets

-8,836

7,589

671

3,061

6,659

-1,206

-8,417

-4,220

-10,856

-25,786

9,099

7,988

8,649

20,158

-7,253

-14,870

1,546

-4,651

8,142

15,833

4,952

16,766

9,730

6,148

2,237

5,001

-9,490

-8,806

-10,067

-511

-565

-406

6,708

320

14,936

1,063

-2,759

4,957

0

0

0

Conversion of convertible debt, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,112

0

0

0

-

-

-

-

283,319

269,921

238,409

238,382

105

0

0

0

-

-

-

-

-

-

-

-

Accrual for inventory purchases related to the acquisition of the Merck PKU Business

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs reclassified into additional paid-in-capital as a result of conversion of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Release of escrow balance for purchase of San Rafael Corporate Center

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Equipment acquired through capital leases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,679

1,679

1,313

0

0

0

Change in asset retirement obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Changes in contingent acquisition consideration payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0